248 related articles for article (PubMed ID: 35454933)
1. Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.
McGowan R; Sally Á; McCabe A; Moran BM; Finn K
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454933
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in pancreatic adenocarcinoma: current perspectives.
Swords DS; Firpo MA; Scaife CL; Mulvihill SJ
Onco Targets Ther; 2016; 9():7459-7467. PubMed ID: 28003762
[TBL] [Abstract][Full Text] [Related]
3. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
4. Application of liquid biopsy for surgical management of pancreatic cancer.
Nagai M; Sho M; Akahori T; Nakagawa K; Nakamura K
Ann Gastroenterol Surg; 2020 May; 4(3):216-223. PubMed ID: 32490335
[TBL] [Abstract][Full Text] [Related]
5. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H
Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
8. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.
Berger AW; Schwerdel D; Reinacher-Schick A; Uhl W; Algül H; Friess H; Janssen KP; König A; Ghadimi M; Gallmeier E; Bartsch DK; Geissler M; Staib L; Tannapfel A; Kleger A; Beutel A; Schulte LA; Kornmann M; Ettrich TJ; Seufferlein T
Theranostics; 2019; 9(5):1280-1287. PubMed ID: 30867830
[TBL] [Abstract][Full Text] [Related]
9. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer.
Khomiak A; Brunner M; Kordes M; Lindblad S; Miksch RC; Öhlund D; Regel I
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33147766
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.
Kruger D; Lahoud N; Yako YY; Devar J; Smith M
PLoS One; 2022; 17(1):e0262439. PubMed ID: 35020761
[TBL] [Abstract][Full Text] [Related]
11. Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC.
Shao H; Zhang Y; Yan J; Ban X; Fan X; Chang X; Lu Z; Wu Y; Zong L; Mo S; Yu S; Chen J
Onco Targets Ther; 2021; 14():2163-2175. PubMed ID: 33790579
[TBL] [Abstract][Full Text] [Related]
12. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection.
Gablo N; Trachtova K; Prochazka V; Hlavsa J; Grolich T; Kiss I; Srovnal J; Rehulkova A; Lovecek M; Skalicky P; Berindan-Neagoe I; Kala Z; Slaby O
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32751582
[TBL] [Abstract][Full Text] [Related]
15. The Significance of Liquid Biopsy in Pancreatic Cancer.
Qi ZH; Xu HX; Zhang SR; Xu JZ; Li S; Gao HL; Jin W; Wang WQ; Wu CT; Ni QX; Yu XJ; Liu L
J Cancer; 2018; 9(18):3417-3426. PubMed ID: 30271504
[TBL] [Abstract][Full Text] [Related]
16. Early detection of pancreatic cancer in the era of precision medicine.
Ahmed TM; Kawamoto S; Lopez-Ramirez F; Yasrab M; Hruban RH; Fishman EK; Chu LC
Abdom Radiol (NY); 2024 May; ():. PubMed ID: 38761272
[TBL] [Abstract][Full Text] [Related]
17. Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma.
Wang C; Wang J; Cui W; Liu Y; Zhou H; Wang Y; Chen X; Chen X; Wang Z
Onco Targets Ther; 2021; 14():1441-1451. PubMed ID: 33664577
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.
Hernandez YG; Lucas AL
World J Gastrointest Oncol; 2016 Jan; 8(1):18-29. PubMed ID: 26798434
[TBL] [Abstract][Full Text] [Related]
19. Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.
Brancaccio M; Natale F; Falco G; Angrisano T
Genes (Basel); 2019 Dec; 11(1):. PubMed ID: 31877923
[TBL] [Abstract][Full Text] [Related]
20. Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma-a systematic review and meta-analysis.
Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Juhász MF; Erőss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
Transl Res; 2022 Jun; 244():126-136. PubMed ID: 35066189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
